Currently, most antidepressants function by boosting levels of serotonin in the brain, a chemical which allows nerve cells in the brain to communicate with each other. However, such treatments can take weeks with an effect and only work in around 50 percent of patients. It is hoped the new drugs will be more effective and quicker to take effect. This gene research will help to provide brand-new targets for the medications and improve knowledge of the key causes of depression. Researchers will establish a microchip holding 800 genes to test those are active in healthy and depressed pets and humans. They’ll test the effects of these depression-related genes by altering their activity in genetically modified mice.Today In a paper published, researchers from Spinifex and their collaborators released the first clinical data on a compound that binds to AT2, called EMA401. Results from the placebo-controlled, phase 2 trial suggest that EMA401, which blocks the receptor, can blunt lingering nerve discomfort due to damage due to the shingles virus. AT2 is 1 of 2 receptors recognized to bind angiotensin II just. Several medicines that block the various other receptor, AT1, have previously received market acceptance for hypertension, diabetic nephropathy and congestive center failing.